Notes From the Field: Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code–Level Social Vulnerability — United States, December 23, 2021–August 28, 2022


Equitable access to COVID-19 therapeutics is a critical aspect of the distribution program led by the U.S. Department of Health and Human Services (HHS).* Two oral antiviral products, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio),§ received emergency use authorization (EUA) from the Food and Drug Administration (FDA) in December 2021, to reduce the risk for COVID-19–associated hospitalization and death for those patients with mild to moderate COVID-19 who are at higher risk for severe illness (1,2). HHS has been distributing these medications at no cost to recipients since their authorization. Data collected from provider sites during December 23, 2021–May 21, 2022, indicated substantial disparities in the population-adjusted dispensing rates in high social vulnerability (high-vulnerability) zip codes compared with those in medium- and low-vulnerability zip codes (3). Specifically, dispensing rates for the 4-week period during April 24–May 21, 2022, were 122 per 100,000 residents (19% of overall population-adjusted dispensing rates) in high-vulnerability zip codes compared with 247 (42%) in medium-vulnerability and 274 (39%) in low-vulnerability zip codes. This report provides an updated analysis of dispensing rates by zip code–level social vulnerability and highlights important intervention strategies.

Data on dispensed numbers of COVID-19 oral antiviral treatment courses are obtained at regular intervals (at least twice per week) from each provider site receiving medications. The HHS Health Partner Ordering Portal is used by oral antiviral provider partners, including those in all U.S. states and jurisdictions, the Federal Retail Pharmacy Therapeutics Program, and Federal entities (e.g., Indian Health Service, Federal Bureau of Prisons, and the U.S. Department of Defense), to order oral antivirals at no cost and to report inventory and product use. Total courses of Paxlovid and Lagevrio dispensed were analyzed by week and zip-code social vulnerability level, using the zip code of the dispensing site. Zip codes were classified as having low, medium, or high social vulnerability, using the same methodology that was used in a previous report**,†† (3).This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.§§

Overall dispensing of oral antivirals increased 57%, from 643 per 100,000 persons during April 24–May 21, 2022, to 1,012 during July 31–August 28. Compared with data collected during April 24–May 21, dispensing during the most recent 4-week period (July 31–August 28) increased to 315 per 100,000 persons (31% of overall population-adjusted dispensing rates) in high vulnerability zip codes, 367 (36%) in medium-vulnerability zip codes, and 331 (33%) in low-vulnerability zip codes (Figure), representing increases in dispensing rates of 159%, 48%, and 21%, respectively. These data indicate a narrowing of the dispensing gap among high-vulnerability and medium-and low-vulnerability zip codes; at the same time, overall dispensing increased.

HHS worked closely with states and territories to improve equitable dispensing, with a focus on increasing education and awareness¶¶ and enhancing distribution efforts, including COVID-19–focused teleprescribing programs, mobile test-to-treat sites, prepositioning of oral antivirals at provider sites in high-vulnerability zip codes, and increased distribution to federally qualified health centers. These efforts were designed to reduce barriers to access by making it easier to satisfy the requirements necessary to receive a clinical assessment to obtain a prescription and begin oral antiviral medication within 5 days of symptom onset. Although both oral antivirals continue to be prescribed primarily by physicians or advanced practice providers, on July 6, 2022, FDA updated the Paxlovid EUA to allow state-licensed pharmacists to prescribe it for an individual patient under certain conditions, including having sufficient data on the patient’s medical history and use of other medications.*** However, pharmacy prescribing of Paxlovid has not yet been widely implemented because of these limitations on prescribing and unclear reimbursement structure for pharmacists to prescribe. Increased dispensing in high-vulnerability zip codes represents valuable progress toward improving access to COVID-19 medications among populations disproportionately affected by the pandemic; however, additional work is needed. Limitations of this analysis include reliance on sites’ self-reported dispensing data, lack of patient-specific data (including demographic and clinical outcome data), and lack of correlative analysis of COVID-19 incidence to overall dispensing rates in specific zip codes.

The COVID-19 therapeutics program represents the largest scale HHS distribution of antivirals, with approximately 16 million COVID-19 treatment courses delivered through August 2022. Ensuring equitable access to antivirals is essential to improving patient outcomes.


MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.



Source link

Ozinize
Logo
Shopping cart